Search

Author/Creator Cheng, A-L

1. 127POutcomes based on albumin‐bilirubin (ALBI) grade in the phase III CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC). (24th November 2019)

Authors:
Chan, S L; Miksad, R; Cicin, I; Chen, Y; Klumpen, H J; Kim, S; Lin, Z Z; Youkstetter, J; Sen, S; Cheng, A-L; El-Khoueiry, A B; Meyer, T; Kelley, R K; Abou-Alfa, G K
Journal:
Annals of oncology
Issue:
Volume 30(2019)Supplement 9
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. 151OPractice patterns, radiologic tumor response, and deterioration of liver function after transarterial chemoembolization (TACE): Final analysis of OPTIMIS in Korea and other regions. (25th November 2018)

Authors:
Heo, J; Cheng, A-L; Raoul, J-L; Peck-Radosavljevic, M; Kudo, M; Nakajima, K; Bayh, I; Lin, S-M; Lee, H C
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 9
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. 199TiPPhase III (COSMIC-312) study of cabozantinib (C) in combination with atezolizumab (A) vs sorafenib (S) in patients (pts) with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy. (24th November 2019)

Authors:
Yau, T; Rimassa, L; Cheng, A-L; Park, J-W; Braiteh, F; Chaudhry, A; Benzaghou, F; Thuluvath, P; Hazra, S; Milwee, S; Tan, B; Sinha, R; Kayali, Z K; Zhu, A X; Kelley, R K
Journal:
Annals of oncology
Issue:
Volume 30(2019)Supplement 9
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. 59PDFinal analysis of serum biomarkers in patients (pts) from the phase III study of lenvatinib (LEN) vs sorafenib (SOR) in unresectable hepatocellular carcinoma (uHCC) [REFLECT]. (23rd October 2018)

Authors:
Finn, R S; Kudo, M; Cheng, A-L; Wyrwicz, L; Ngan, R; Blanc, J F; Baron, A D; Vogel, A; Ikeda, M; Piscaglia, F; Han, K-H; Qin, S; Minoshima, Y; Kanekiyo, M; Ren, M; Dairiki, R; Tamai, T; Dutcus, C E; Funahashi, Y; Evans, T R J
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. 697PA phase I, open-label, multi-center, dose-escalation study of codrituzumab, an anti-glypican-3 monoclonal antibody, in combination with atezolizumab in patients with locally advanced or metastatic hepatocellular carcinoma. (23rd October 2018)

Authors:
Cheng, A-L; Yen, C-J; Okusaka, T; Ikeda, M; Hsu, C-H; Wu, S-Y; Morizane, C; Hashimoto, Y; Ueshima, K; Ohtomo, T; Tanaka, T; Kudo, M
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. 702POutcomes by baseline alpha-fetoprotein (AFP) levels in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (HCC). (23rd October 2018)

Authors:
Kelley, R K; El-Khoueiry, A B; Meyer, T; Rimassa, L; Merle, P; Chan, S L; Tran, A; Parnis, F; Tam, V C; Cattan, S; Markby, D W; Clary, D O; Cheng, A-L; Abou-Alfa, G K
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗